SIX WEEKS VS SIX MONTHS OF VALGANCICLOVIR IN INFANTS WITH SYMPTOMATIC CONGENITA

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 这项研究的主要目的是比较六周和六个月的伐更昔洛韦口服液对患有症状性先天性巨细胞病毒(CMV)疾病的婴儿听力结果的影响。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The primary objective of this study is to compare the impact on hearing outcomes of six weeks versus six months of valganciclovir oral solution in infants with symptomatic congentical cytomegalovirus (CMV) disease.